Enanta Pharmaceuticals (ENTA) Total Liabilities (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Total Liabilities came in at $198.1 million in Q1 2026, down 13.66% YoY from $229.5 million in Q1 2025, and down 2.36% on a QoQ basis from $202.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Total Liabilities (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Total Liabilities data on file, last reported at $198.1 million in Q1 2026.
- Quarterly Total Liabilities fell 13.66% year-over-year to $198.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.1 million (down 13.66% YoY) and the FY2025 annual result came in at $216.0 million, down 12.84% from the prior year.
- Total Liabilities slipped to $198.1 million in Q1 2026, from $202.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $257.3 million in Q2 2023 to a low of $46.7 million in Q4 2022.
- A 5-year average of $179.0 million and a median of $221.8 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities decreased 16.92% — and 2023, when it soared 445.34%.
- Tracing ENTA's Total Liabilities over 5 years: stood at $46.7 million in 2022, then surged by 406.7% to $236.6 million in 2023, then increased by 0.09% to $236.8 million in 2024, then slipped by 14.32% to $202.9 million in 2025, then dropped by 2.36% to $198.1 million in 2026.
- The last three Total Liabilities figures came in at $198.1 million (Q1 2026), $202.9 million (Q4 2025), and $216.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 195.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 195.80 Mn |
| Mar 31, 2026 | 198.12 Mn |
| Dec 31, 2025 | 202.91 Mn |
| Sep 30, 2025 | 216.02 Mn |
| Jun 30, 2025 | 221.75 Mn |
| Mar 31, 2025 | 229.46 Mn |
| Dec 31, 2024 | 236.83 Mn |
| Sep 30, 2024 | 247.84 Mn |
| Jun 30, 2024 | 249.91 Mn |
| Mar 31, 2024 | 247.44 Mn |
| Dec 31, 2023 | 236.62 Mn |
| Sep 30, 2023 | 245.54 Mn |
| Jun 30, 2023 | 257.35 Mn |
| Mar 31, 2023 | 57.07 Mn |
| Dec 31, 2022 | 46.70 Mn |
| Sep 30, 2022 | 54.08 Mn |
| Jun 30, 2022 | 47.19 Mn |
| Mar 31, 2022 | 48.24 Mn |
| Dec 31, 2021 | 56.21 Mn |
| Sep 30, 2021 | 39.36 Mn |